DL-AP3
Based on 1 publication(s) in Google Scholar
DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.0%
- CAS 番号: 5652-28-8
- 分子式: C3H8NO5P
- 分子量:169.07
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
MedChemExpress(MCE)の使用を引用している文献 DL-AP3
MoreEndogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
|
mGluR 1 |
mGluR 5 |
DL-AP3 (10 µM, 6 h) alleviates oxygen-glucose deprivation (OGD)-induced injury (cell viability) in primary neurons[1].
DL-AP3 (10 µM, 6 h) recovers the decreased levels of p-Akt1 and the increase of cytochrome C induced by OGD in primary neurons[1].
DL-AP3 (1-100 µM) inhibits activity of rat brain phosphoserine phosphatase, with an IC50 of 187 µM and Ki of 77 µM[2].
DL-AP3 (10 μM, 10 min) together with SKF81297 (5 μM) induces a significant Long-term potentiation (LTP) in the slices of Fmr1 KO mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary neurons with oxygen-glucose deprivation (OGD) treatment
-
Concentration:10 µM
-
Incubation Time:24 h or 72 h
-
Result:Attenuated the inhibitory effect of OGD on neuronal viability.
-
Cell Line:Primary neurons with oxygen-glucose deprivation (OGD) treatment
-
Concentration:10 µM
-
Incubation Time:6 h
-
Result:Increased the decreased levels of p-Akt1, and decreased the increase of cytochrome C.
DL-AP3 (4.0-12.0 mg/animal, i.c.v. infusion, 100 μL) blocks development of visceral pain symptoms and neuroendocrinological changes in the blood plasma of sheep[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fmr1 KO mice[3]
-
Dosage:4 mg/kg with SKF81297 (1 mg/kg)
-
Administration:i.p., for 5 weeks.
-
Result:Reduced the distance traveled by Fmr1 KO mice (open-field test).
Reduced the swim latency on the final day in the Fmr1 KO mice (Morris Water Maze test).
-
Animal Model:Sheep with visceral pain evoked by colonic distension (CD)[4]
-
Dosage:4.0-12.0 mg/animal
-
Administration:i.c.v. infusion, 100 μL
-
Result:Decreased intensity from appearance of clinical signs of visceral pain caused by CD test.
Diminished the increase of plasma cortisol, E, NE and DA concentrations caused by visceral pain provoked by CD episode.
化学情報
-
CAS 番号 5652-28-8
-
性状 Solid
-
分子量 169.07
-
分子式 C3H8NO5P
-
Color White to off-white
-
SMILES
NC(CP(O)(O)=O)C(O)=O
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
H2O : 5 mg/mL (29.57 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Cui D, et al. DL-2-amino-3-phosphonopropionic acid protects primary neurons from oxygen-glucose deprivation induced injury. Bosn J Basic Med Sci. 2017 Feb 21;17(1):12-16. [Content Brief]
[2]. Hawkinson JE, et al. The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur J Pharmacol. 1996 Jun 27;307(2):219-25. [Content Brief]
[3]. Xu ZH, et al. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener. 2012 May 28;7:24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.9147 mL | 29.5735 mL | 59.1471 mL | 147.8677 mL |
| 5 mM | 1.1829 mL | 5.9147 mL | 11.8294 mL | 29.5735 mL | |
| 10 mM | 0.5915 mL | 2.9574 mL | 5.9147 mL | 14.7868 mL | |
| 15 mM | 0.3943 mL | 1.9716 mL | 3.9431 mL | 9.8578 mL | |
| 20 mM | 0.2957 mL | 1.4787 mL | 2.9574 mL | 7.3934 mL | |
| 25 mM | 0.2366 mL | 1.1829 mL | 2.3659 mL | 5.9147 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.